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Background: The clinical characteristics distinguishing treatable thiamine transporter-2 deficiency (ThTR2) due to
SLC19A3 genetic defects from the other devastating causes of Leigh syndrome are sparse.
Methods: We report the clinical follow-up after thiamine and biotin supplementation in four children with ThTR2
deficiency presenting with Leigh and biotin-thiamine-responsive basal ganglia disease phenotypes. We established
whole-blood thiamine reference values in 106 non-neurological affected children and monitored thiamine levels in
SLC19A3 patients after the initiation of treatment. We compared our results with those of 69 patients with ThTR2
deficiency after a review of the literature.
Results: At diagnosis, the patients were aged 1 month to 17 years, and all of them showed signs of acute
encephalopathy, generalized dystonia, and brain lesions affecting the dorsal striatum and medial thalami. One
patient died of septicemia, while the remaining patients evidenced clinical and radiological improvements shortly
after the initiation of thiamine. Upon follow-up, the patients received a combination of thiamine (10–40 mg/kg/day)
and biotin (1–2 mg/kg/day) and remained stable with residual dystonia and speech difficulties. After establishing
reference values for the different age groups, whole-blood thiamine quantification was a useful method for
treatment monitoring.
Conclusions: ThTR2 deficiency is a reversible cause of acute dystonia and Leigh encephalopathy in the pediatric
years. Brain lesions affecting the dorsal striatum and medial thalami may be useful in the differential diagnosis of
other causes of Leigh syndrome. Further studies are needed to validate the therapeutic doses of thiamine and how
to monitor them in these patients.
Keywords: Thiamine transporter 2 deficiency, Biotin responsive basal ganglia disease, SLC19A3, Leigh syndrome,
Lactic acidosis, Thiamine, Biotin, Striatal necrosis, DystoniaResumen
Antecedentes: Las características clínicas distintivas del déficit tratable del trasportador de tiamina tipo 2 (ThTR2)
debido a defectos genéticos del SLC19A3 de las otras causas devastadores del síndrome de Leigh son escasas.
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Métodos: Presentamos el seguimiento clínico después de la administración de suplementos de tiamina y biotina a cuatro
niños con deficiencia ThTR2 que presentaban fenotipos de biotin-thiamine responsive basal ganglia disease y síndrome de
Leigh. Hemos establecido valores de referencia de tiamina en sangre total en 106 niños sin patología neurológica y
monitorizamos los niveles de tiamina en pacientes con mutación del SLC19A3 después del inicio del tratamiento. Hemos
comparado nuestros resultados con los de 69 pacientes con deficiencia ThTR2 después de una revisión de la literatura.
Resultados: Al momento del diagnóstico , los pacientes tenían entre 1 mes a 17 años, y todos ellos mostraron signos
de encefalopatía aguda, distonía generalizada, y lesiones cerebrales que afectan el cuerpo estriado dorsal y el tálamo
medial. Un paciente murió de septicemia, mientras que el resto de pacientes evidenciaron mejoras clínicas y
radiológicas poco después del inicio de la tiamina. Al seguimiento, los pacientes recibieron una combinación de
tiamina (10–40 mg/kg/día) y biotina (1–2 mg/kg/día) y se mantuvieron estables, aunque con distonía y dificultades del
habla residual. Después de establecer valores de referencia para los diferentes grupos de edad, la cuantificación de
tiamina en sangre total demuestra ser un método útil para el seguimiento del tratamiento.
Conclusiones: La deficiencia ThTR2 es una causa reversible de la distonía aguda y síndrome de Leigh en la edad
pediátrica. Las lesiones cerebrales que afectan el cuerpo estriado dorsal y tálamo medial pueden ser útiles en el
diagnóstico diferencial de otras causas de síndrome de Leigh. Se necesitan más estudios para validar las dosis de
tiamina y la monitorización terapéutica de estos pacientes.Background
Acute encephalopathy with bilateral striatal necrosis in
childhood includes several disorders of infectious, auto-
immune, metabolic and genetic origin [1-5]. One of these
diseases is thiamine transporter-2 deficiency (ThTR2,
OMIM#607483), a recessive inherited defect due to muta-
tions in the SLC19A3 gene that cause acute and recurrent
episodes of encephalopathy with dystonia, seizures and
brain injury that respond extremely well to the early ad-
ministration of thiamine and biotin [6-20]. However, bio-
chemical or neuroimaging criteria for diagnosis are not
available, and timely and effective treatment relies on a
high index of clinical suspicion. Of particular interest is
the distinction of ThTR2 from other untreatable causes of
Leigh syndrome, such as defects in the nuclear and mito-
chondrial genes encoding components of the oxidative-
phosphorylation system or the pyruvate metabolism,
causing a devastating disorder with similar clinical and
radiological features in the pediatric age.
We aim to describe the phenotypes of four children
with mutations in the SLC19A3 gene, comparing their
clinical, biochemical, radiological and genetic data with
all of the formerly reported patients and discussing the
possible clinical and radiological clues for the distinction
of ThTR2 from other causes of irreversible basal ganglia
necrosis, especially Leigh syndrome. Moreover, we re-
port the follow-up after thiamine and biotin supplemen-
tation and the utility of monitoring whole-blood thiamine
concentrations.
Methods
Patients
Four children with SLC19A3 gene mutations were diag-
nosed at a tertiary university children’s hospital (HospitalSant Joan de Déu, University of Barcelona) during the past
4 years.
Patients 1, 3 and 4 were diagnosed at the onset of
acute encephalopathy and received early treatment with
thiamine and biotin. A clinical description of these pa-
tients at diagnosis has been previously reported [11,19].
Patient 2 was identified by mutation screening for the
SLC19A3 gene in 11 children with Leigh syndrome who
had normal respiratory chain enzyme analyses. Leigh pa-
tients were previously analyzed for mitochondrial DNA
mutations and for candidate nuclear genes associated
with Leigh syndrome, all with negative results. The pa-
tients were evaluated using a standardized protocol, in-
cluding a complete physical and neurological examination
and biochemical studies at diagnosis, at 4 weeks and every
6 months after the onset of encephalopathy. Brain MRIs
were performed at diagnosis and at 6 to 12 months after
the initiation of treatment. Samples were obtained in ac-
cordance with the Helsinki Declaration of 1964, as revised
in October 2013 in Fortaleza, Brazil. Ethical permission
for the studies was obtained from the Research & Ethics
Committee of the Hospital Sant Joan de Déu.
Neuroimaging
MRI examinations were performed on a 1.5-T magnet sys-
tem (Signa Excite HD, Milwaukee, WI, USA), obtaining a
sagittal T1-weighted, axial fast-spin echo with fluid-
attenuated inversion recovery (FLAIR) and T2-weighted im-
aging. Diffusion weighted imaging was performed in patient
1. Two pediatric neuro-radiologists reviewed the images.
Laboratory studies
Blood concentrations of lactate and pyruvate were mea-
sured by standard automated spectrometric procedures.
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lyzed following previously reported procedures [21,22].
The concentration of thiamine and its metabolites
(thiamine monophosphate (TMP) and thiamine diphos-
phate (TDP)) were analyzed in whole-blood EDTA sam-
ples by high-performance liquid chromatography (HPLC)
with fluorescence detection (Perkin Elmer, series 200,
Norwalk, CT, USA) according to a modified reported pro-
cedure [23]. Whole-blood thiamine, TMP and TDP refer-
ence values were established in 106 children (59% males)
referred to our hospital for minor surgical interventions.
Exclusion criteria were the presence of chronic diseases,
malnutrition and special diets. Whole-blood thiamine was
quantified in patients 1, 2 and 3 at 6 months and
12 months after the onset of treatment.
Molecular analysis of the SLC19A3 gene
Genomic DNA from the blood samples of 11 patients
with Leigh syndrome were used for the mutation ana-
lysis of the SLC19A3 gene (RefSeq accession number
NM_025243.3_ [mRNA]). The coding region and the
flanking intron-exon boundaries were PCR amplified
with primers based on the Ensembl genome browserTable 1 The clinical, biochemical and genetic data of the four
Patients 1 2
Origin Morocco Spain
Mutation SLC19A3 gene c.68G > T in homozygosis c.1079dupT/ c.980-14A
Phenotype Leigh syndrome Leigh syndrome
Sex and Onset Male, 1 month Male, 13 months
Encephalopathy Lethargy, vomiting Irritability, continuous c
Extrapiramidal features Hypotonia, jitteriness,
dystonia, opisthotonus,
tremor
Hypotonia, status dysto
ophistotonus, tremor
Cranial nerves Dysphagia Dysphagia, nystagmus,
Others Pyramidal signs Ataxia, weight loss, hep
jaundice
Plasma Lactate
(RR 0,7 – 2,4 mmol/L)
8.6 2.3
Plasma Pyruvate
(RR 0,03-0,1 mmol/L)
0.14 0.1
Lactate/Pyruvate ratio
(RR 11–30)
19.1 23.4
Alpha Alanine
(RR 167 – 439 μmol/L)
637 355
CSF Lactate
(RR 1,1 – 2,2 mmol/L)
7.1 1.7
Organic acid analysis
in urine
High excretion of
alpha-ketoglutarate
(11463 mmol/mol
creatinine)
High excretion of 2-hy
isobutyric, 2-hydroxy-is
2,4-dihydroxybutyric
BTBGD: Biotin-thiamine responsive basal ganglia disease.entry ENSG00000135917. The amplicons were sequenced
and analyzed as previously described [24]. The mutation
nomenclature used follows that described at http://www.
hgvs.org./mutnomen/.
Systematic review of the literature
We searched MEDLINE (through PubMed) using the fol-
lowing keywords: #1 SLC19A3, #2 thiamine transporter-2,
#3 Leigh encephalopathy, #4 ThTR2 and #5 biotin re-
sponsive basal ganglia disease. The number of hits at 02/
01/2014 was 50, 190, 44, 5, and 14, respectively. A total
of 15 clinical studies (4 case reports, 11 quantitative
series) and 1 guideline/clinical practice proposal were fi-
nally selected [6-20].
Results
Patients
Table 1 summarizes the clinical, biochemical and genetic
data of the four patients with SLC19A3 defects.
Four patients suffering SLC19A3 mutations had no
relevant family history for neurological diseases and
were normally developing children until the onset of
symptoms (mean age 3 years, range 1 month - 8 years).patients with thiamine transporter-2 deficiency
3 4
Spain Spain
> G c.74dupT/ c.980-14A > G c.74dupT/ c.980-14A > G
BTBGD BTBGD
Female, 4 years Male, 15 years
rying Agitation, lethargy Agitation, coma
nicus, Paroxysmal dystonia,
generalized dystonia,
tremor
Status dystonicus, akinetic-rigid
syndrome, tremor
strabismus Anarthria, dysphagia Nystagmus, ptosis, diplopia,
dysarthria, vertigo, facial
dyskinesias/hyposthesias
atomegaly, None Pyramidal signs, rabdomyolisis,
dysautonomia, generalized
seizures
1.6 1.2
0.21 0.13
11.5 18.2
300 370
Not performed 1.8
droxy acids,
ovaleric acid,
Normal Normal
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identified in patients 2 and 4 (gastroenteritis, trauma,
strong physical exercise and an upper respiratory tract
infection).
All of the patients showed signs of encephalopathy
and focal or generalized dystonia. In all of the cases, dys-
tonia progressed to be generalized, and 2 patients had
associated opisthotonus. Patients 2 and 4 suffered status
dystonicus and were transferred to the intensive care
unit for profound sedo-analgesia. Patient 2 received di-
azepam, levomepromazine and chlorpromazine, fol-
lowed by midazolam from day 27 to day 34, when he
died. Patient 4 received trihexyphenidyl and diazepam
for several days until the spasm and posture were under
control.
Other clinical features at onset of the disease are re-
ported in Table 1.
Clinical improvement was evidenced shortly after the
initiation of thiamine in patients 1, 3 and 4 (the daily
doses varied from 15 to 30 mg/kg/day and were given
orally in two or three divided doses), combined with
biotin in patient 1 (10 mg/day). Patient 2 suffered
septicemia caused by Enterobacter cloacae and hepatic
and cardiac failure and died 34 days after admission.
Thiamine was empirically initiated 6 days before he
died (initial doses of 150 mg daily, followed later by 1 g,
twice a day).Figure 1 Axial T2 FSE demonstrated bilateral and symmetrical involve
(P.1), 2 (P.2), 3 (P.3) and 4 (P.4). In patients 2, 3 and 4, the head of the caPatient follow-up
Currently, patients 1, 3 and 4 are 25 months, 8 years and
23 years old, respectively. The median follow-up of these
patients is 57 months (range 22 – 99 months). As of the
last visit, they are receiving a combination of thiamine
(10 – 40 mg/kg/d) and biotin (1 – 2 mg/kg/d) (Table 1),
and they remain stable under this treatment and have
not suffered any new episodes of encephalopathy.
Patient 1 developed independent gait at 19 months,
and on his last examination at the age of 25 months he
was walking, with occasional falls due to gait-induced
dystonia. He plays and eats independently, but upper
limb dystonia and thumb adduction partially interfere
with his fine motor skills. He has oro-mandibular dys-
tonia and expressive language delay, but his language
comprehension and cognitive skills are in the average
range for his age. A physical examination also showed
pyramidal signs in the lower limbs. He has begun an in-
tensive physiotherapy program.
Patient 3 is asymptomatic at 8 years old, and her
neurological examination is normal. She attends a nor-
mal school and achieves good academic performance.
She developed a nephrotic syndrome at 6 years old that
was responsive to oral corticosteroids.
Patient 4 is 23 years old and has mild dysarthria and
dysphagia. He shows intermittent facial dyskinesia and
eye-blinking, as well as dystonic posturing of his rightment of the putamina and medial thalamic nuclei in patients 1
udates were also affected.
Figure 2 Axial T2 FSE of patient 3 (P.3) at the level of the basal
ganglia and of patient 1 at the level of the peri-rolandic region
(P.1) and the basal ganglia (P.1) before and after treatment.
There is a dramatic improvement of the lesions after thiamine
supplementation.
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activities that require fine motor skills, such as button-
ing, tying shoes or opening bottles. He is engaged in
gainful employment and exercises regularly.
Neuroimaging
The brain MRIs of the four patients in the acute phase
showed lesions in both the dorsal striatum and the med-
ial thalamic nuclei (Figure 1). Putamen involvement was
diffuse in patients 2, 3 and 4 and was limited to the pos-
terior region in patient 1. A concentric lesion of the
head of the caudate was observed in patients 2, 3 and 4.
There was variable cortical and subcortical involvement
of the hemispheres: in patient 1, lesions had a peri-
rolandic distribution; in patients 2 and 4, they were
patchily distributed across both cerebral hemispheres.
Diffusion weighted imaging was performed in patient 1
showing low ADC values in the putamina and peri-
rolandic cortex. High lactate peaks were detected in pa-
tients 2 and 4 on MR spectroscopy.
The follow-up MRIs performed at age 6 months (patient
1), 7 years (patient 3) and 20 years (patient 4) showed an
improvement in the signal abnormalities in all of the pa-
tients (Figure 2). Residual abnormal signal intensity and
volume loss were observed in the putamen (patients 1, 3
and 4) and head of the caudate (patients 3 and 4). The
cortical and subcortical lesions disappeared in patient 3,
but volume loss was observed at the peri-rolandic region
in patient 1 (Figure 2).
Laboratory studies
The biochemical analysis at diagnosis showed high lac-
tate levels in patient 1 (Table 1). Patient 2 had normal
lactate concentrations until he presented with septi-
cemia, when lactic acid increased to 16 mmol/L. Alanine
was increased only in patient 1. Organic acids showed
high excretion of alpha-ketoglutarate in patient 1 and
mild excretion of 2-hydroxy acids, isobutyric, 2-hydroxy-
isovaleric acid and 2,4-dihydroxybutyric in patient 2.
The analysis of thiamine, TDP and TMP isoforms in
whole-blood samples in the control patients showed that
the TDP isoform represented 85% of the whole thiamine
concentration. Therefore, TDP values were used for
treatment monitoring. The reference whole-blood TDP
values were stratified into two age groups, as a statisti-
cally significant negative correlation was observed be-
tween whole-blood TDP values and the age (r = −0.290;
p = 0.003) (Figure 3).
On the last follow-up visit, Patient 3 was taking biotin
(2 mg/kg/day) and thiamine (10 mg/kg/day) and patient 4
was taking biotin (2 mg/kg/day) and thiamine (15 mg/kg/
day). Both patients had TDP values above the upper limit
of our reference range (Figure 4). Patient 1 was receiving
biotin (1.2 mg/kg/day) and thiamine (40 mg/kg/day), buthis TDP concentrations did not reach the upper limit of
the age reference range. Persistent lactic acidemia (mean
2.69 mmol/L, range 2.1–3.46) was detected in the follow-
up of this patient.Molecular studies
A Sanger sequencing of the SLC19A3 gene in patients 1,
3 and 4 had identified missense, small duplication and
splicing mutations, all of which were carried either in a
homozygous or heterozygous fashion [11,19]. The muta-
tion analysis in Patient 2 disclosed two different changes,
both of which created premature stop codons in the
ThTR2 protein sequence. One of the changes was the
previously described c. 980-14A >G, and the other change
was the novel duplication, c.1079dupT, with a predictable
effect on the protein of p.Leu360Phefs*38. A schematic
representation of the SLC19A3 mutations present in our
four patients and in all previously reported patients is
shown in Figure 4.
*
161
*
113
‡  326  
‡  323 
§ 250
§ 215
Figure 3 Box-plot representations of the whole-blood TDP concentrations divided into two intervals: < 5 years (n = 67): 90.3 nmol/L
(38.8-188.4) (median, range); > 5 years (n = 39): 68.8 (34.2-114.8) (median, range). The Mann–Whitney U test showed significantly different
values for TDP when comparing both groups (U = 731, p < 0.001). The TDP values of patients 1(*), 2 (‡) and 3 (§) under thiamine treatment are
also represented in the figure. The length of the boxes indicates the interquartile space (P25-P75), the horizontal line represents the median (P50),
and the bars indicate the range.
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A summary of the clinical data from the literature re-
view in 69 patients is reported in Table 2. Most of the
patients (80%) presented with symptoms before the age
of 12 years (age onset 3.5 ± 4.6 years (mean ± SD), range
1 month – 20 years). The patients exhibited the follow-
ing phenotypes: biotin-thiamine responsive basal ganglia
disease (BTBGD) (N = 46), Leigh encephalopathy (N = 23)
and Wernicke encephalopathy (N = 2). Figure 4 shows the
age at onset of all of the formerly reported patients, as well
as their clinical phenotypes and related genotypes.
In regard to treatment, there were some reports of using
biotin alone (N = 2) [6,9,10], thiamine alone (N = 3) [8,13],
and biotin combined with thiamine (N = 5) [10,11,14,16,
18,19]. In two studies on Leigh patients, the diagnosis was
performed retrospectively, and treatment with vitamins
was introduced late in the evolution of symptoms in a few
patients, with very poor outcomes [12,13].
Discussion
We describe four patients with ThTR2 deficiency pre-
senting with acute encephalopathic episodes and gener-
alized dystonia between 1 month and 15 years of age.
Their dystonia was improved when each of them were
administered thiamine, with the exception of the patient
treated late in the evolution of the disease. The datafrom the previously reported patients with SLC19A3
mutations showed that either focal or generalized dys-
tonia, in combination with decreased consciousness and
seizures, were the most common clinical features at on-
set and were reported in more than fifty percent of the
patients [6-20], reflecting that ThTR2 deficiency is an
important cause of reversible dystonia in children.
Hence, a trial with thiamine should be indicated in every
case of acute dystonia. Patients also presented with other
less common extrapyramidal and pyramidal features,
cranial nerve palsy, dysautonomia, rhabdomyolisis, jaun-
dice and other systemic symptoms.
The literature review showed that most patients with
SLC19A3 mutations experienced an onset of the disease
between 1 month and 12 years of age. Two-thirds of the
patients were classified as BTBGD and the remaining
patients were classified as having Leigh and Wernicke
encephalopathies. However, there is probably a clinical
continuum among patients that, in view of the reported
mutational spectrum, appears to be biologically more
plausible. In fact, patient 2 with Leigh syndrome in our
series carried the mutation c.980-14A > G, which has
been previously described in children with a BTBGD
phenotype [10,11], and patient 1 who also presented
with infantile lactic acidosis and Leigh syndrome har-
bored the mutation c.68G > T, which has been previously
Figure 4 The upper figure shows a distribution of the age at onset in all reported patients with ThTR2 deficiency and the related
clinical phenotypes. The lower figure shows a schematic representation of all reported SLC19A3 mutations and the related clinical phenotypes.
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tients with the same mutations had different ages at onset
(e.g., c.1264A >G [14,15] and c.20C > A [13]). Considering
the dense genetic interaction network that sustains a dis-
ease phenotype, it is probable that a combination of yet
unknown genetic and environmental factors may be re-
sponsible for the different age presentations and related
phenotypes [25,26].
Despite the genetic heterogeneity of our patients and
the wide age range of disease at onset, all of them pre-
sented symmetrical involvement of the dorsal striatum
and medial thalamic nuclei. In the older patients, the
head of the caudate was always affected, and the cortical
and subcortical lesions showed a diffuse and patchy dis-
tribution in the cerebral hemispheres [14,15]. In the
newborn, the caudate was not affected, and there was a
selective involvement of the peri-rolandic area [19]. The
differences in the distribution of the brain lesions ob-
served in our patients probably depend on the regional
variations in the energetic demands according to the dif-
ferent ages. Although this pattern of brain lesions maynot be specific, it can be useful in suggesting the diagno-
sis of a SLC19A3 defect. In line with our results, the lit-
erature review showed that the most frequent brain
areas involved in ThTR2 deficient patients were, in order
of frequency, the caudate, putamen and thalamus,
followed by the cerebellum, brainstem and cerebral
hemispheres [6-20].
Regarding the biochemical findings, lactic acidemia
and high excretion of organic acids were detected during
acute metabolic decompensations in two infants in our
series. Thiamine is an essential cofactor of 3 mitochon-
drial enzymes: pyruvate dehydrogenase complex, alpha-
ketoglutarate dehydrogenase, and branched-chain alpha-
keto acid dehydrogenase. These enzymes are involved
in the oxidative decarboxylation of pyruvate, alpha-
ketoglutarate, and branched chain amino acids, respect-
ively. The biochemical abnormalities detected in our
patients could be due to the decreased activity of these
thiamine-dependent mitochondrial enzymes [19]. The
older children showed normal biochemical analyses for
plasma, urine and CSF, and lactic acid accumulation was
Table 2 The clinical and radiological features of patients with thiamine transporter-2 deficiency reported in the literature
Number of patients Number of patients
Patients 69 Dead patients 23
Age (years ± SD) 3.5 ± 4.3 Symptoms at follow up
Male/Female 36/33 Tetraparesia/Dystonia 32
Trigger events 40 Cognitive impairment 23
Symptoms at onset Dysphagia 13
Encephalopathy/Lethargy 57 Epilepsy 11
Seizure 47 Dysarthria 10
Generalized and focal dystonia 38 Respiratory support 4
Dysarthria/Anarthria 28 Ataxia 3
Ataxia 25
Dysphagia 21 MRI
Pyramidal signs 19 Caudate 55
Abnormal ocular movement 17 Putamen 55
Developmental delay 12 Thalami 31
Opisthotonus 11 Cerebellum 22
Rigidity/Rigid akinetic syndrome 11 Brainstem 19
Tremor 4 Subcortical WM 16
Chorea 2 Cerebral cortex 13
Jitteriness 2 Globus pallidus 8
Dystonic status 2 Medulla 3
Dysautonomia 2 Lactate on spectroscopy 6
Ptosis 2
The table shows a list of signs and symptoms at onset and at follow-up, as well as MRI abnormalities. Seizures include myoclonic jerks, epileptic spams, focal and
generalized seizure, epilesia partialis continua and status epilepticus. Abnormal ocular movements include nystagmus, oculogyric crisis, oculomotor nerve palsy,
ophtalmoplegia and sunset phenomenon. Symptoms reported only once: rhabdomyolisis, facial dyskinesia. SD: Standard Deviation.
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thors have described high amounts of lactic acid in the
serum and high excretion of organic acids in the urine of
patients with fatal infantile Leigh phenotypes (Table 1)
[12,13] but normal biochemical profiles in children classi-
fied as having BTBGD phenotypes [8-10,14].
We observed a dramatic response to high doses of
thiamine in the three patients who were treated during
the first days of encephalopathy. Clinical follow-up
showed a complete clinical and radiological recovery in
one patient, but the other two patients showed residual
dystonia, speech difficulties, and necrotic changes in the
dorsal striatum and the frontal cortex.
Even though thiamine was initiated four weeks after
the onset of symptoms, patient 2 died at 14 months of
age. In other reported cases of fatal infantile Leigh and
SLC19A3 defects, the lesions progressed to cystic degen-
eration and severe atrophy, suggesting that the prognosis
of these patients is poor and largely depends on the early
administration of biotin and thiamine [8,10,15]. Al-
though SLC19A3 deficiency is considered to be a treat-
able entity, the literature review showed that sixty
percent of previously reported patients with eitherBTBGD or a Leigh phenotype had poor outcomes, in-
cluding early death, tetraparesis, dystonia or cognitive
impairment. At the other end of the spectrum, patients
with Wernicke encephalopathy showed lesions that se-
lectively affected the periaqueductal grey matter, which
disappeared when thiamine was initiated [8].
When establishing the whole-blood thiamine reference
values, we found that TDP was the most concentrated
thiamine isoform, similar to other studies [23,27]. For
this reason, treatment monitoring relied on whole-blood
TDP concentrations. Patients treated with 10 to 40 mg/
kg/day of thiamine were clinically stable for a mean
follow-up of 57 months. At these doses, TDP levels
remained above the upper limit of the reference values
in patients 3 and 4. Conversely, in patient 1, the TDP
concentrations remained in the reference range, and he
presented persistent acidosis. These data led to the suspi-
cion of poor family adherence to the treatment, which was
confirmed and corrected with the participation of a social
worker in the follow-up program. This patient did not
present any clinical relapse, even though lactic acid con-
centrations were persistently elevated, perhaps due to the
absence of relevant trigger factors during follow-up.
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of vitamins that should be administered in SLC19A3 defi-
cient patients, and the documented doses of thiamine and
biotin vary from 100 to 900 mg per day and from 2 to
12 mg/kg per day, respectively [6-20]. It is likely that
higher doses are required when trigger factors, such as
fever or trauma, are present [18]. Initial reports described
a good response to biotin as a monotherapy [8]. However,
a recent description by Tabarki et al. reported that a high
proportion of patients treated with biotin only showed re-
currences of encephalopathy compared with those who
received biotin and thiamine simultaneously [14].
We detected pathogenic mutations in the SLC19A3
gene in 1 of 11 patients with Leigh syndrome. Similarly,
Gerards et al. reported that 2 of 17 Leigh patients were
positive for SLC19A3 mutations [13]. The MRI pattern
of brain injury involving the dorsal striatum and medial
thalamic nuclei in patients with SLC19A3 defect may be
useful to distinguish this disorder from other causes of
Leigh syndrome. Interestingly, some correlations have
been described between MRI findings and specific gen-
etic defects. In patients with ATPase 6 mutations MRI
typically shows necrosis in the putamina, demyelization
in the corona radiata and cerebellar and brainstem atro-
phy in the final stages [28]. Patients with PDHc defi-
ciency usually present with lesions in the basal ganglia,
brainstem and dentate nuclei, being the globus pallidus
frequently involved [29]. A common pattern of brain
MRI in patients with Complex I deficiency consists of
brainstem and striatal lesions (putamina more frequently
than the caudate and pallidum) [30]. MRS may show lac-
tate peaks during the acute phase in SLC19A3 defects
and in other causes of Leigh syndrome [11].
In view of the overlapping phenotypes that may exist
between ThTR2 deficiency and mitochondrial disorders
causing Leigh encephalopathy, it seems advisable to ini-
tiate empirically biotin and thiamin in every patient with
Leigh syndrome. However, it is concerning that in a re-
cent report on the practice patterns of mitochondrial
disease physicians in North America, only 3 of 32 med-
ical doctors administered thiamine and other B complex
vitamins [31].
In conclusion, thiamine transporter-2 deficiency is an
inherited recessive disease that affects the central ner-
vous system during development and may present as
Leigh syndrome in infants, mimicking untreatable mito-
chondrial disorders. A characteristic MRI pattern of
caudate, putamen and medial thalamus involvement, in
association with lactic acid accumulation and high ex-
cretion of organic acids in urine in infants, suggests the
diagnosis. It is of utmost importance to start early treat-
ment with thiamine and biotin because the process may
be at least partially reversible. Currently, there is an ur-
gent need for validated tools for early diagnosis andtreatment monitoring. In our experience, thiamine quan-
tification by the HPLC method in whole-blood samples
appears to be a useful method for the evaluation of the
adherence to treatment. Further studies are needed to
validate the therapeutic doses of thiamine and how to
monitor them in these patients.
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